Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sparsentan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA known ✓ | P25101 | 8/20 | 1.00 |
| ▸ | AGTR1 known ✓ | P30556 | 4/20 | 1.00 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.51 |
| ▸ | ACHE | P22303 | 3/20 | 0.46 |
| ▸ | EDNRB | P24530 | 1/20 | 0.46 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sparsentan SCHEMBL29706489 | 1.00 | EDNRA (1.00) | EDNRAAGTR1AGTR2ACHEEDNRB | |
| SCHEMBL27418345 | 0.99 | EDNRA (0.99) | EDNRAAGTR1AGTR2ACHEEDNRB | |
| SCHEMBL26867622 | 0.99 | EDNRA (0.97) | EDNRAAGTR1AGTR2ACHEEDNRB | |
| SCHEMBL6540396 | 0.95 | EDNRA (0.91) | EDNRAAGTR1AGTR2ACHEEDNRB | |
| SCHEMBL7546311 | 0.95 | EDNRA (0.91) | EDNRAAGTR1AGTR2ACHELTB4R2 | |
| SCHEMBL26867624 | 0.95 | EDNRA (0.90) | EDNRAAGTR1AGTR2ACHEEDNRB | |
| SCHEMBL26877305 | 0.94 | EDNRA (0.89) | EDNRAAGTR1AGTR2ACHEEDNRB | |
| SCHEMBL26867623 | 0.94 | EDNRA (0.89) | EDNRAAGTR1AGTR2ACHEEDNRB | |
| SCHEMBL6541152 | 0.94 | EDNRA (0.89) | EDNRAAGTR1AGTR2ACHEEDNRB | |
| SCHEMBL6540125 | 0.94 | EDNRA (0.89) | EDNRAAGTR1AGTR2ACHEEDNRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 413 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4719402-A1 | SPARSENTAN FOR USE IN A METHOD OF TREATING IGA-MEDIATED DISEASES | Travere Therapeutics, Inc. (US) | 2026-04-08 | — | — | EP | claimed |
| EP-4709364-A1 | THERAPEUTIC FORMULATIONS FOR KIDNEY DISEASE COMPRISING REPAGERMANIUM OR PROPAGERMANIUM AND/OR AT1R BLOCKERS | Dimerix Bioscience Pty Ltd (AU) | 2026-03-18 | — | — | EP | claimed |
| US-12577300-B2 | Neutralizing antibodies to human endothelin | Father Flanagan's Boys' Home Business (US) | 2026-03-17 | — | — | US | claimed |
| US-20260021079-A1 | NOX INHIBITORS FOR USE IN THE TREATMENT OF ALPORT SYNDROME | CALLIDITAS THERAPEUTICS SUISSE SA (CH) | 2026-01-22 | — | — | US | claimed |
| US-20250352511-A1 | METHODS OF TREATING FOCAL SEGMENTAL GLOMERULOSCLEROSIS WITH ATRASENTAN | CHINOOK THERAPEUTICS INC (US) | 2025-11-20 | — | — | US | claimed |
| US-12465605-B2 | Methods and materials for gender-dependent treatment of cardiovascular dysfunction | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2025-11-11 | — | — | US | claimed |
| US-20250325523-A1 | BIPHENYL SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF KIDNEY DISEASES OR DISORDERS | TRAVERE THERAPEUTICS INC (US) | 2025-10-23 | — | — | US | claimed |
| US-20250325522-A1 | BIPHENYL SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF KIDNEY DISEASES OR DISORDERS | Retrophin, Inc. | 2025-10-23 | — | — | US | claimed |
| EP-4616867-A1 | COMBINATION OF ENDOTHELIN RECEPTOR ANTAGONIST AND GLUCOCORTICOID FOR TREATING IGA NEPHROPATHY | Sanreno Therapeutics (Shanghai) Limited (CN) | 2025-09-17 | — | — | EP | claimed |
| EP-4608396-A1 | TREATMENT OF IGA NEPHROPATHY USING AN ENDOTHELIN RECEPTOR ANTAGONIST AND AN APRIL BINDING ANTIBODY | Chinook Therapeutics, Inc. (US) | 2025-09-03 | — | — | EP | claimed |
| EP-1741713-A2 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | Bristol-Myers Squibb Company (US) | 2007-01-10 | — | — | EP | claimed |
| US-20040127515-A1 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | PHARMACOPEIA, LLC | 2004-07-01 | — | — | US | claimed |
| US-20040106833-A1 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | PHARMACOPEIA, LLC | 2004-06-03 | — | — | US | claimed |
| US-6638937-B2 | As antihypertensive agents; for therapy of disorders related to renal, glomerular and mesangial cell function; therapy of endotoxemia or endotoxin shock as well as hemorrhagic shock; useful in alleviation of pain associated cancer | BRISTOL-MYERS SQUIBB CO. | 2003-10-28 | — | — | US | claimed |
| US-20020143024-A1 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | PHARMACOPEIA, LLC | 2002-10-03 | — | — | US | claimed |
| EP-1237888-A2 | BIPHENYL SULFONAMIDES AS DUAL ANGIOTENSIN ENDOTHELIN RECEPTOR ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2002-09-11 | — | — | EP | claimed |
| EP-1094816-A4 | BIPHENYL SULFONAMIDES AS DUAL ANGIOTENSIN ENDOTHELIN RECEPTOR ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2001-12-19 | — | — | EP | claimed |
| WO-2001044239-A2 | BIPHENYL SULFONAMIDES AS DUAL ANGIOTENSIN ENDOTHELIN RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB CO. (US) | 2001-06-21 | — | — | WO | claimed |
| EP-1094816-A1 | BIPHENYL SULFONAMIDES AS DUAL ANGIOTENSIN ENDOTHELIN RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-05-02 | — | — | EP | claimed |
| WO-2000001389-A1 | BIPHENYL SULFONAMIDES AS DUAL ANGIOTENSIN ENDOTHELIN RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB CO. (US) | 2000-01-13 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127515-A1 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | EDNRB, AGTR2, EDNRA | EDNRA 3/4885AGTR1 4/4885AGTR2 2/4885 |
| US-20260021079-A1 | NOX INHIBITORS FOR USE IN THE TREATMENT OF ALPORT SYNDROME | NOX1, NOX5, NOX4 | EDNRA 2998/4885AGTR1 10/4885AGTR2 17/4885 |
| US-12577300-B2 | Neutralizing antibodies to human endothelin | IGLV6-57, ETV1, VEGFA | EDNRA 241/4885AGTR1 672/4885AGTR2 533/4885 |
| US-20250325523-A1 | BIPHENYL SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF KIDNEY DISEASES OR DISORDERS | REN, ATP6V1B1, VHL | EDNRA 706/4885AGTR1 35/4885AGTR2 22/4885 |
| US-20020143024-A1 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | EDNRB, AGTR2, EDNRA | EDNRA 3/4885AGTR1 4/4885AGTR2 2/4885 |
| US-20040106833-A1 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | EDNRB, AGTR2, EDNRA | EDNRA 3/4885AGTR1 4/4885AGTR2 2/4885 |
| US-20250352511-A1 | METHODS OF TREATING FOCAL SEGMENTAL GLOMERULOSCLEROSIS WITH ATRASENTAN | REN, AGT, FRS2 | EDNRA 20/4885AGTR1 8/4885AGTR2 6/4885 |
| US-20250325522-A1 | BIPHENYL SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF KIDNEY DISEASES OR DISORDERS | REN, ATP6V1B1, VHL | EDNRA 706/4885AGTR1 35/4885AGTR2 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.